Table 2.

Suggested minimum data collection and assessment intervals¹to be used with treatment plans

			Assessment Intervals
Proposed Variables2			Baseline Visit	Follow-up visits: 1–2 weeks, 1 month, 3 month, 6 months, 9 months
History
	•  Demographics
		▪  DOB
		▪  Gender	X
		▪  Race and ethnicity
	•  Date(s) of onset of Symptoms
		▪  Fever	X
		▪  Rash
		▪  Joint symptoms
	•  Pre-enrollment treatment     history for SJIA		X
	•  Current Medications and     doses		X	X
	•  Comorbid Diagnoses		X
	•  Fever of sJIA in the past week		X	X
	•  Rash of sJIA in the past week		X	X
	•  Duration of morning stiffness		X	X
	•  Serositis in the past week		X	X
	•  Patient has MAS (impression     of treating physician)		X	X
Patient reported outcomes and global assessments
	•  Pain		X	X
	•  HRQOL		X	X
	•  Physical function		X	X
	•  Parent/patient global     assessment of disease activity		X	X
	•  Physician global assessment     of disease activity		X	X
Physical exam
	•  Height, weight, BMI		X	X
	•  Rash		X	X
	•  Active joint count		X	X
	•  Lymphadenopathy		X	X
	•  Hepatomegaly		X	X
	•  Splenomegaly		X	X
	•  Serositis		X	X
Labs
	•  CBC (wbc, hemoglobin,     platelet count)		X	X
	•  C-reactive protein		X	X
	•  Erythrocyte sedimentation rate		X	X
	•  Ferritin		X	X
	•  LDH		X	X
Treatment plan related items
	•  Serious adverse events or     important medical event			X
	•  If plan discontinued, rationale			X
	•  Number of IV steroid pulses, if     Any			X
	•  Uveitis status at last eye exam			X

¹Data is collected at baseline, 1–2 weeks, 1, 3, 6, 9 months. Data collection is encouraged at changes in treatment (even if it does not occur at a scheduled time point). Monthly phone follow-up recommended. Any additional visits in between these time points are at the discretion of the physician and data may or may not be collected.

²Not included in table, malignancy and infection work-up, screen for tuberculosis at baseline (and then annually).